IRVINE, California, United States, April 7, 2026
Johnson & Johnson MedTech announced the European launch of VARIPULSE™ Pro, an advanced pulsed field ablation (PFA) platform, following CE Mark approval, marking a significant step forward in the treatment of atrial fibrillation (AF). The new system introduces a next-generation pulse sequence designed to improve procedural efficiency, enhance workflow, and maintain high standards of safety and precision, reinforcing the company’s leadership in cardiovascular MedTech innovation.
Next-Generation PFA Technology Enhances Speed and Precision
The VARIPULSE Pro platform incorporates a new pulse sequence with a lower temperature profile and significantly faster ablation capability, achieving procedures that are up to five times faster than previous configurations while maintaining equivalent lesion quality. This advancement enables clinicians to perform more efficient and streamlined procedures without compromising safety or effectiveness, a critical factor in high-volume electrophysiology settings.
The system integrates seamlessly with the CARTO™ 3 mapping system, utilizing advanced tissue proximity indicators and real-time imaging capabilities to ensure precise lesion delivery and optimal patient outcomes. Early clinical use has demonstrated smooth operability, improved workflow efficiency, and consistent procedural performance, highlighting the platform’s potential to transform catheter-based cardiac ablation procedures.
Addressing Growing Burden of Atrial Fibrillation
Advertisement
Atrial fibrillation remains the most common cardiac arrhythmia globally, affecting over 50 million people worldwide, with prevalence expected to increase due to aging populations and lifestyle factors. PFA technology offers a non-thermal ablation approach, reducing the risk of damage to surrounding tissues and improving safety profiles compared to traditional thermal ablation techniques.
The launch of VARIPULSE Pro reflects Johnson & Johnson’s commitment to advancing minimally invasive cardiac therapies, providing physicians with innovative tools to treat complex arrhythmias more effectively. The platform’s ability to deliver rapid, precise, and reproducible ablation supports improved clinical outcomes and patient safety, addressing a significant unmet need in cardiovascular care.
The system is currently being evaluated in the VARIPURE multicenter post-market study, which aims to generate robust real-world clinical evidence supporting its long-term safety and efficacy.
Expanding Clinical Evidence and Physician Training Initiatives
Johnson & Johnson plans to showcase the VARIPULSE Pro platform at EHRA 2026, including live case demonstrations, hands-on training sessions, and scientific presentations, emphasizing its commitment to clinical education and adoption of advanced technologies. The company will also present 12-month interim data from the VARIPURE study, providing valuable insights into the real-world performance of pulsed field ablation systems.
By combining clinical evidence generation with physician training initiatives, Johnson & Johnson aims to accelerate the global adoption of PFA technology, enabling healthcare providers to deliver high-quality, patient-centered cardiac care.
Notably, VARIPULSE Pro is currently not approved in the United States, highlighting ongoing regulatory pathways and the importance of regional approvals in medical device commercialization strategies.
The European launch of VARIPULSE™ Pro represents a major advancement in pulsed field ablation technology, offering enhanced speed, precision, and safety for the treatment of atrial fibrillation. With strong integration of advanced mapping systems, real-world clinical validation, and physician training, the platform is poised to transform electrophysiology procedures and improve patient outcomes.
As the demand for minimally invasive and highly effective cardiac therapies continues to grow, innovations like VARIPULSE Pro underscore the critical role of MedTech innovation, regulatory approval, and clinical validation in shaping the future of cardiovascular healthcare.
Source: Johnson & Johnson press release
